Phospholipid-binding proteins differ in their capacity to induce autoantibodies and murine systemic lupus erythematosus

Lupus

Volumn 23, Issue 8, 2014, Pages 752-768

  Levine, J S ^a,b   Subang, R ^c   Setty, S ^a   Cabrera, J ^d   Laplante, P ^c   Fritzler, M J ^e   Rauch, J ^c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b JESSE BROWN VA MEDICAL CENTER   (United States)

^c RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d ADVOCATE LUTHERAN GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF CALGARY   (Canada)

Author keywords

Antiphospholipid antibodies; Murine models; Phospholipid binding proteins; Systemic lupus erythematosus; 2 glycoprotein I

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; BETA2 GLYCOPROTEIN 1; COLONY STIMULATING FACTOR 1; CXCL3 CHEMOKINE; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PHOSPHOLIPID BINDING PROTEIN; PLASMINOGEN[GLUTAMIC ACID]; PROTEIN S; PROTHROMBIN; RANTES; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CELL SURFACE; CONTROLLED STUDY; CROSS REACTION; DISEASE SEVERITY; GLOMERULONEPHRITIS; IMMUNE RESPONSE; IMMUNIZATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROLIFERATIVE GLOMERULONEPHRITIS; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; C57BL MOUSE; COMPARATIVE STUDY; DISEASE MODEL; FEMALE; IMMUNOLOGY; PHYSIOLOGY;

ANIMALS; AUTOANTIBODIES; BETA 2-GLYCOPROTEIN I; DISEASE MODELS, ANIMAL; FEMALE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED C57BL; PROTHROMBIN;

EID: 84903542578     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203314525676     Document Type: Article

References (34)

1. Levine JS, Subang R, Nasr SH, et al. Immunization with the apoptotic cell-binding protein, b2-glycoprotein I, in the presence of lipopolysaccharide recapitulates both autoantibody emergence and nephritis of human SLE. J Immunol 2006; 177: 6504-6516.
2. Tolomeo T, Rico de Souza A, Roter E, et al. T cells demonstrate a Th1-biased response to native b2-glycoprotein I in a murine model of anti-phospholipid antibody induction. Autoimmunity 2009; 42: 292-295.
3. Price BE, Rauch J, Shia MA, et al. Anti-phospholipid autoantibodies bind to apoptotic, but not viable, thymocytes in a beta 2- glycoprotein I-dependent manner. J Immunol 1996; 157: 2201-2208.
4. Balasubramanian K, Chandra J, Schroit AJ. Immune clearance of phosphatidylserine-expressing cells by phagocytes. The role of beta2-glycoprotein I in macrophage recognition. J Biol Chem 1997; 272: 31113-31117.
5. Manfredi AA, Rovere P, Heltai S, et al. Apoptotic cell clearance in systemic lupus erythematosus. II. Role of beta2-glycoprotein I. Arthritis Rheum 1998; 41: 215-223.
6. D'Agnillo P, Levine JS, Subang R, Rauch J. Prothrombin binds to the surface of apoptotic, but not viable, cells and serves as a target of lupus anticoagulant autoantibodies. J Immunol 2003; 170: 3408-3422.
7. Webb JH, Blom AM, Dahlbäck B. Vitamin K-dependent protein S localizing complement regulator C4b-binding protein to the surface of apoptotic cells. J Immunol 2002; 169: 2580-2586.
8. Anderson HA, Maylock CA, Williams JA, Paweletz CP, Shu H, Shacter E. Serum-derived protein S binds to phosphatidylserine and stimulates the phagocytosis of apoptotic cells. Nat Immunol 2003; 4: 87-91.
9. Hunt JE, Simpson RJ, Krilis SA. Identification of a region of beta 2-glycoprotein I critical for lipid binding and anti-cardiolipin antibody cofactor activity. Proc Natl Acad Sci U S A 1993; 90: 2141-2145.
10. Stenflo J. Contributions of Gla and EGF-like domains to the function of vitamin K-dependent coagulation factors. Crit Rev Eukaryot Gene Expr 1999; 9: 59-88.
11. Urbanus RT, de Laat B. Antiphospholipid antibodies and the protein C pathway. Lupus 2010; 19: 394-399.
12. Meroni PL, Borghi MO, Raschi E, Tedesco F. Pathogenesis of antiphospholipid syndrome: Understanding the antibodies. Rev Rheumatol 2011; 7: 330-339.
13. Galli M, Borrelli G, Jacobsen EM, et al. Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study. Blood 2007; 110: 1178-1183.
14. Laplante P, Amireault P, Subang R, Dieudé M, Levine JS, Rauch J. Interaction of b2-glycoprotein I with lipopolysaccharide leads to Toll-like receptor 4 (TLR4)-dependent activation of macrophages. J Biol Chem 2011; 286: 42494-42503.
15. Agar C, de Groot PG, Mörgelin M, et al. b2-glycoprotein I: A novel component of innate immunity. Blood 2011; 117: 6939-6947.
16. Dahlbäck B, Villoutreix BO. The anticoagulant protein C pathway. FEBS Lett 2005; 579: 3310-3316.
17. Carrera Silva EA, Chan PY, Joannas L, et al. T cell-derived protein S engages TAM receptor signaling in dendritic cells to control the magnitude of the immune response. Immunity 2013; 39: 160-170.
18. Wurm H. beta 2-Glycoprotein-I (apolipoprotein H) interactions with phospholipid vesicles. Int J Biochem 1984; 16: 511-515.
19. Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349: 1526-1533.
20. de Groot PG, Meijers JC. b2-Glycoprotein I: Evolution, structure and function. J Thromb Haemost 2011; 9: 1275-1284.
21. Meagher LC, Savill JS, Baker A, Fuller RW, Haslett C. Phagocytosis of apoptotic neutrophils does not induce macrophage release of thromboxane B2. J Leukoc Biol 1992; 52: 269-272.
22. Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I. Immunosuppressive effects of apoptotic cells. Nature 1997; 390: 350-351.
23. Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-b, PGE2, and PAF. J Clin Invest 1998; 101: 890-898.
24. Liu K, Iyoda T, Saternus M, Kimura Y, Inaba K, Steinman RM. Immune tolerance after delivery of dying cells to dendritic cells in situ. J Exp Med 2002; 196: 1091-1097.
25. Su RJ, Epp A, Latchman Y, Bolgiano D, Pipe SW, Josephson NC. Suppression of FVIII inhibitor formation in hemophilic mice by delivery of transgene modified apoptotic fibroblasts. Mol Ther 2010; 18: 214-222.
26. Getts DR, Turley DM, Smith CE, et al. Tolerance induced by apoptotic antigen-coupled leukocytes is induced by PD-L1+, IL- 10-producing splenic macrophages and maintained by Tregs. J Immunol 2011; 187: 2405-2417.
27. Natkanski E, Lee WY, Mistry B, Casal A, Molloy JE, Tolar P. B cells use mechanical energy to discriminate antigen affinities. Science 2013; 340: 1587-1590.
28. Harper MF, Hayes PM, Lentz BR, Roubey RA. Characterization of beta2-glycoprotein I binding to phospholipid membranes. Thromb Haemost 1998; 80: 610-614.
29. Metcalf D. The unsolved enigmas of leukemia inhibitory factor. Stem Cells 2003; 21: 5-14.
30. Shen MM, Skoda RC, Cardiff RD, Campos-Torres J, Leder P, Ornitz DM. Expression of LIF in transgenic mice results in altered thymic epithelium and apparent interconversion of thymic and lymph node morphologies. EMBO J 1994; 13: 1375-1385.
31. Bard JB, Ross AS. LIF, the ES-cell inhibition factor, reversibly blocks nephrogenesis in cultured mouse kidney rudiments. Development 1991; 113: 193-198.
32. Morel DS, Taupin JL, Potier M, et al. Renal synthesis of leukaemia inhibitory factor (LIF), under normal and inflammatory conditions. Cytokine 2000; 12: 265-271.
33. Viallard JF, Taupin JL, Miossec V, Pellegrin JL, Moreau BL. Analysis of interleukin-6, interleukin-10 and leukemia inhibitory factor (LIF) production by peripheral blood cells from patients with systemic lupus erythematosus identifies LIF as a potential marker of disease activity. Eur Cytokine Netw 1999; 10: 17-24.
34. Rand JH. A new fish for the b2GPI hook: LPS! Blood 2011; 117: 6743-6744.